Filing Flows › Comparisons › BDTX vs KYMR
Black Diamond Therapeutics vs Kymera Therapeutics: BDTX and KYMR compared
Black Diamond Therapeutics is the larger company: $70.0M of revenue in its latest quarter (Q1 2025) against $65.0M for Kymera Therapeutics (Q2 2026). Black Diamond Therapeutics is more profitable, with an operating margin of 77.9% against -116.3%.
Where the money goes: BDTX and KYMR
Black Diamond Therapeutics (BDTX) · Q1 2025
Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%, net earnings $56.5M, operating cash flow $53.4M. The chart follows the revenue to costs, profit and cash.
Kymera Therapeutics (KYMR) · Q2 2026
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
| Black Diamond Therapeutics (BDTX) | Kymera Therapeutics (KYMR) | |
|---|---|---|
| Latest quarter | Q1 2025 | Q2 2026 |
| Revenue | $70.0M | $65.0M |
| Revenue growth, Y/Y | — | +466% |
| Operating margin | 77.9% | -116.3% |
| Net earnings | $56.5M | −$61.2M |
| Net margin | 80.8% | -94.2% |
| Operating cash flow | $53.4M | −$54.1M |
Questions
Which is bigger, Black Diamond Therapeutics or Kymera Therapeutics?
Black Diamond Therapeutics is the larger company: $70.0M of revenue in its latest quarter (Q1 2025) against $65.0M for Kymera Therapeutics (Q2 2026).
Is Black Diamond Therapeutics or Kymera Therapeutics growing faster?
Black Diamond Therapeutics is more profitable, with an operating margin of 77.9% against -116.3%.
More: Black Diamond Therapeutics earnings · how Black Diamond Therapeutics makes money · Kymera Therapeutics earnings · how Kymera Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 12, 2025; 10-Q filed Aug 5, 2026). Fiscal quarters can end on different dates. Not investment advice.